UnknownPhase 4NCT04910711
Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV
Studying Lethal ataxia with deafness and optic atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Botswana Harvard AIDS Institute Partnership
- Principal Investigator
- Chelsea Morroni, PhD MBChBBotswana Harvard AIDS Institute Partnership
- Intervention
- Dolutegravir(drug)
- Enrollment
- 140 target
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2021 – 2024
Study locations (1)
- Princess Marina Hospital, Gaborone, Botswana
Collaborators
University of Liverpool
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04910711 on ClinicalTrials.govOther trials for Lethal ataxia with deafness and optic atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06374758Accelerated ART Initiation for PWHIV Who Are Out of CareUniversity of Missouri-Columbia
- RECRUITINGNANCT05912270Orchestra in Class, a Novel Booster for Executive Functions and Brain Development in Young Primary School ChildrenSchool of Health Sciences Geneva
- ACTIVE NOT RECRUITINGNANCT06176859Delivery Optimization for Pre-Exposure Prophylaxis (DO PrEP) StudyMassachusetts General Hospital
See all trials for Lethal ataxia with deafness and optic atrophy →